Literature DB >> 20921280

Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy.

S Leboulleux1, D Deandreis, C Escourrou, A Al Ghuzlan, F Bidault, A Aupérin, J P Travagli, J Lumbroso, M Schlumberger, E Baudin.   

Abstract

OBJECTIVE: To make the specificity of fluorodesoxyglucose ((18)FDG) positron emission tomography (PET) precise, in the follow-up of patients with adrenal cancer.
DESIGN: This single centre retrospective study assessed the frequency and outcome of (18)FDG uptake in the remaining adrenal glands after adrenalectomy for adrenocortical carcinoma (ACC) or malignant phaeochromocytoma (PH).
RESULTS: Two hundred and ten (18)FDG PET scans in 62 ACC patients, all under 1,ortho-1,para'-dichloro-diphenyl-dichloro-ethane (o,p'-DDD) treatment, and 30 (18)FDG PET scans in 8 PH patients were reviewed. Abnormal (18)FDG uptake in the remaining adrenal glands was found in 19 (8%) (18)FDG PET scans, in 10 (16%) ACC patients and in none of the PH patients. (18)FDG uptake was found in 4% of the patients before the onset of o,p'-DDD, in 29% of the patients 0-6 months after the onset of o,p'-DDD (P=0.05), in 26% of the patients 6-12 months (P=0.072) after the onset of o,p'-DDD and in 14% of the patients 12-24 months after the onset of o,p'-DDD. It was never found later than 24 months after the onset of o,p'-DDD. Adrenal glands with (18)FDG uptake were normal on computed tomography scans with i.v. contrast agent in all cases. (18)FDG uptake in the remaining adrenal glands decreased and disappeared on subsequent FDG PET imaging in eight of the patients with follow-up available.
CONCLUSIONS: (18)FDG uptake in the remaining adrenal glands occurred in 14-29% of the patients followed for ACC within 24 months after adrenalectomy and onset of o,p'-DDD. This uptake is transient and should not be considered as suspicious for malignancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921280     DOI: 10.1530/EJE-10-0666

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

Review 1.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

2.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

Review 3.  Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.

Authors:  Asha Kandathil; Ka Kit Wong; Daniel J Wale; Maria Chiara Zatelli; Anna Margherita Maffione; Milton D Gross; Domenico Rubello
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

4.  EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Henri J Timmers; Elif Hindié; Benjamin A Guillet; Hartmut P Neumann; Martin K Walz; Giuseppe Opocher; Wouter W de Herder; Carsten C Boedeker; Ronald R de Krijger; Arturo Chiti; Adil Al-Nahhas; Karel Pacak; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

5.  Vasovagal-related stress immediately before FDG injection may increase bilateral adrenal FDG uptake.

Authors:  Megumi Jinguji; Masatoyo Nakajo; Masayuki Nakajo; Yoshiaki Nakabeppu; Takashi Yoshiura
Journal:  Br J Radiol       Date:  2016-03-24       Impact factor: 3.039

Review 6.  Molecular imaging of adrenal neoplasms.

Authors:  Clara C Chen; Jorge A Carrasquillo
Journal:  J Surg Oncol       Date:  2012-05-24       Impact factor: 2.885

7.  Adrenal Myelolipoma Masquerading as an Adrenal Malignancy.

Authors:  Davida A Robinson; Margaret Kemeny; Juliana E Muchinyi; Madiha Yasin; Nilda I Montes; Sandeep Tuli; Radhika Jaiswal; Amanda Carter; Michal-Ann Derezil; Hanna Jang; David Reich
Journal:  Case Rep Endocrinol       Date:  2022-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.